Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer

Tanya Stoyanova, Mireille Riedinger, Shu Lin, Claire M. Faltermeier, Bryan A. Smith, Kelvin X. Zhang, Catherine C. Going, Andrew S. Goldstein, John K. Lee, Justin M. Drake, Meghan A. Rice, En Chi Hsu, Behdokht Nowroozizadeh, Brandon Castor, Sandra Y. Orellana, Steven M. Blum, Donghui Cheng, Kenneth J. Pienta, Robert E. Reiter, Sharon J. PitteriJiaoti Huang, Owen N. Witte

Research output: Contribution to journalArticlepeer-review


Metastatic castration-resistant prostate cancer (CRPC) is the primary cause of prostate cancer-specific mortality. Defining new mechanisms that can predict recurrence and drive lethal CRPC is critical. Here, we demonstrate that localized high-risk prostate cancer and metastatic CRPC, but not benign prostate tissues or low/intermediate-risk prostate cancer, express high levels of nuclear Notch homolog 1, translocation-associated (Notch1) receptor intracellular domain. Chronic activation of Notch1 synergizes with multiple oncogenic pathways altered in early disease to promote the development of prostate adenocarcinoma. These tumors display features of epithelial-to-mesenchymal transition, a cellular state associated with increased tumor aggressiveness. Consistent with its activation in clinical CRPC, tumors driven by Notch1 intracellular domain in combination with multiple pathways altered in prostate cancer are metastatic and resistant to androgen deprivation. Our study provides functional evidence that the Notch1 signaling axis synergizes with alternative pathways in promoting metastatic CRPC and may represent a new therapeutic target for advanced prostate cancer.

Original languageEnglish (US)
Pages (from-to)E6457-E6466
JournalProceedings of the National Academy of Sciences of the United States of America
Issue number42
StatePublished - Oct 18 2016


  • Cancer
  • Notch1
  • Prostate

ASJC Scopus subject areas

  • General

Fingerprint Dive into the research topics of 'Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer'. Together they form a unique fingerprint.

Cite this